FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biotechnology. Described is a peptide capable to induce cytotoxic (killer)T-cells. Presented are medications containing the described peptide that are intended for induction of immunity against malignant tumours, for tumours treatment and/or prevention, for induction of antigen-presenting cells highly capable to induce tumour-reactive T-cells and for induction of tumour-reactive T-cells. Presented is an antibody specifically bonded to the described peptide. Described are an extracted tumour-reactive killer T-cell that is induced in vitro by way of stimulation by the described peptide, a tumour-reactive helper T-cell induced in vitro by way of stimulation by the described peptide, an antigen-presenting cell representing a complex of an HLA molecule and the described peptide.
EFFECT: invention allows to intensify immunity with a patient suffering from metastasis cancer or resistant cancer when surgery treatment, chemotherapy and radiation therapy are practically inapplicable.
10 cl, 4 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FOXM1 PEPTIDE AND MEDICINAL AGENT CONTAINING SAID PEPTIDE | 2008 |
|
RU2487886C2 |
| CDH3-PEPTIDE AND DRUG PREPARATION CONTAINING IT | 2008 |
|
RU2483078C2 |
| TUMOUR-REJECTING GLYPICAN-3 (GPC3)-DERIVATIVE ANTIGENIC PEPTIDES USED FOR HLA-A2-POSITIVE PATIENTS, AND PHARMACEUTICAL PRODUCT CONTAINING SAID PEPTIDES | 2006 |
|
RU2395519C2 |
| CDCA1 PEPTIDE AND PHARMACEUTICAL DRUG CONTAINING IT | 2008 |
|
RU2486195C2 |
| CDC45L PEPTIDES AND VACCINES CONTAINING SAME | 2010 |
|
RU2562160C2 |
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| EPITOPIC PEPTIDES RAB6KIFL/KIF20A AND VACCINES CONTAINING THEM | 2009 |
|
RU2532105C2 |
| URLC10-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | 2015 |
|
RU2700881C2 |
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
| MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THEM | 2012 |
|
RU2612905C2 |
